- Castells-Nobau, Anna
- Moreno-Navarrete, José Maria
- Vega-Correa, Lisset de la
- Puig, Irene
- Arnoriaga-Rodríguez, María
- Pérez-Brocal, Vicente
- Moya, Andrés
- Fernández-Real, José Manuel
- Mayneris-Perxachs, Jordi
Castells-Nobau A., et al., [Background]: The microbiota is emerging as a key factor in the predisposition to insulin resistance and obesity., [Objective]: To understand the interplay among gut microbiota and insulin sensitivity in multiple tissues., [Design]: Integrative multiomics and multitissue approach across six studies, combining euglycaemic clamp measurements (used in four of the six studies) with other measurements of glucose metabolism and insulin resistance (glycated haemoglobin (HbA1c) and fasting glucose)., [Results]: Several genera and species from the Proteobacteria phylum were consistently negatively associated with insulin sensitivity in four studies (ADIPOINST, n=15; IRONMET, n=121, FLORINASH, n=67 and FLOROMIDIA, n=24). Transcriptomic analysis of the jejunum, ileum and colon revealed T cell-related signatures positively linked to insulin sensitivity. Proteobacteria in the ileum and colon were positively associated with HbA1c but negatively with the number of T cells. Jejunal deoxycholic acid was negatively associated with insulin sensitivity. Transcriptomics of subcutaneous adipose tissue (ADIPOMIT, n=740) and visceral adipose tissue (VAT) (ADIPOINST, n=29) revealed T cell-related signatures linked to HbA1c and insulin sensitivity, respectively. VAT Proteobacteria were negatively associated with insulin sensitivity. Multiomics and multitissue integration in the ADIPOINST and FLORINASH studies linked faecal Proteobacteria with jejunal and liver deoxycholic acid, as well as jejunal, VAT and liver transcriptomic signatures involved in the actin cytoskeleton, insulin and T cell signalling. Fasting glucose was consistently linked to interferon-induced genes and antiviral responses in the intestine and VAT. Studies in Drosophila melanogaster validated these human insulin sensitivity-associated changes., [Conclusion]: These data provide comprehensive insights into the microbiome-gut-adipose-liver axis and its impact on systemic insulin action, suggesting potential therapeutic targets.Cite Now., This work was partly supported by EU- FP7 FLORINASH (Health- F2- 2009- 241913) to RB, MF and JMFR, by Instituto de Salud Carlos III (Madrid, Spain) through the projects PI15/01934, PI18/01022, PI21/01361 and PMP21/00072 (co- funded by the European Union/Plan de Recuperación, Transformación y Resiliencia) to JMFR, PI19/01712 to JMM- N, and PI20/01090 and PI23/00575 to JM- P (co- funded by the European Union under the European Regional Development Fund (FEDER). ’A way to make Europe’), the project CNS2023- 144218 funded by MCIN/ AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR to JM- P and Generalitat de Catalunya 2021 SGR 01263. This work has also been co- f inanced by the Spanish Ministry of Science, Innovation and Universities with funds from the European Union NextGenerationEU, from the Recovery, Transformation and Resilience Plan (PRTR- C17.I1) and from the Autonomous Community of Catalonia within the framework of the Biotechnology Plan Applied to Health through the project PPCC- ADGUT to JM- P. JM- P and ACN are funded by Instituto de Salud Carlos III (Madrid, Spain) through the Miguel Servet Program CP18/00009 and Sara Borrell Program CD20/00051 (co- funded by the European Union under the European Social Fund ’Investing in your future’), respectively. IDIBGI is a CERCA centre from the ’CERCA Programme/Generalitat de Catalunya’. The Cohort SIMMUNIDIA has been promoted by the Rangueil Hospital of Toulouse, France and received an essential f inancial support from the Federation Française de Recherche en Diabetologie, technical support from the departments of Gastroenterology and Diabetes. This study has been granted from the Fondation Francophone pour la Recherche sur le Diabète, sponsored by the FFD, Abbott, AstraZeneca, Lilly, MSD, Novo Nordisk and Sanofi. We thank Emeline Lhuilier at GeT- Santé facility (I2MC, Inserm, Génome et Transcriptome, GenoToul, Toulouse, France) for its contribution to the sequencing data (US1426, INRAE, Génome et Transcriptome, GenoToul, Toulouse, France) and Vaiomer SAS (Labège innopole France) for 16SrRNA sequencing. We thank Vincent Azalbert for then immune cell preparation. We thank Professor Louis Buscail, Professor Barbara Bournet and Mrs Emilie Bergereau (Department of Gastroenterology, CHU de Toulouse, Toulouse, France) for their contribution to the SIMMUNIDIA study. FLORINASH is also funded by GutsUK and Diabetes UK grants to M- ED and supported by the NIHR Imperial Biomedical Research Centre and by grants from the French National Research Agency (ANR- 10- LABX- 46 (European Genomics Institute for Diabetes)), the National Center for Precision Diabetic Medicine, which is jointly supported by the French National Agency for Research (ANR- 18- IBHU- 0001), the European Union (FEDER), the Hauts- de- France Regional Council (Agreement 20001891/NP0025517), the European Metropolis of Lille (agreement 2019_ ESR_11) and site ULNE (R- 00220- TALENT- DUMAS), which is also jointly funded by ANR (ANR- 16- IDEX0004- ULNE), the Hauts- de- France Regional Council (20002845) and the European Metropolis of Lille. This research was conducted within the context of the CNRS–ULille–Imperial International Research Project in Integrative Metabolism ’METABO- LIC’., Peer reviewed